Janus kinase 3 (JAK3)-dependent phosphatidyl inositol 4,5-bisphosphate (PIP2) signaling and its effect on arterial thrombus formation

P. Münzer (Tübingen)1, F. Kollotzek (Tübingen)2, M. Manke (Tübingen)3, G. Lingens (Tübingen)3, M. Fischer (Tübingen)1, M. Gawaz (Tübingen)2, M. Lämmerhofer (Tübingen)4, O. Borst (Tübingen)2
1Universitätsklinikum Tübingen Innere Medizin III, Kardiologie und Angiologie Tübingen, Deutschland; 2Universitätsklinikum Tübingen Innere Medizin III, Kardiologie und Kreislauferkrankungen Tübingen, Deutschland; 3Universitätsklinikum Tübingen Kardiovaskuläre Thrombo-Inflammation & Translationale Thrombokardiologie Tübingen, Deutschland; 4University Tübingen, Institute of Pharmaceutical Sciences Tübingen, Deutschland

Background: Adhesion of platelets to subendothelial collagen after plaque rupture results in a phospholipase C (PLC) evoked hydrolysis of inositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) with subsequent rising cytosolic Ca2+ concentrations ([Ca2+]i). Increasing [Ca2+]i is a prerequisite for platelet activation, which is essential for the development of thrombotic vascular occlusions. Janus kinase 3 (JAK3) is a member of the Janus family protein-tyrosine kinases which is strongly expressed in platelets and affects pseudopodia formation, degranulation and aggregation in human platelets. Although STAT3, a downstream target of JAK3, plays a crucial role in Ca2+ signaling and platelet aggregation, less is known about the impact of JAK3 in IP3-dependent platelet activation and thrombus formation.
Objective: The present study explored the role of JAK3 in PIP2 and IP3 signaling mechanisms during Ca2+-dependent platelet activation culminating in thrombotic vascular occlusions in JAK3-deficient (jak3-/-) mice.
Methods and Results: Upon stimulation of the major platelet receptor glycoprotein VI (GPVI) by means of collagen-related peptide (CRP)-dependent activation, fura-2-AM spectrofluorometric Ca2+ measurements revealed a diminished increase of [Ca2+]i in platelets from jak3-/- mice when compared to platelets from corresponding wildtype littermates. Consequently, in comparison to naïve platelets, flow cytometry and light transmission aggregometry revealed a significantly blunted activation-dependent integrin αIIbβ3 activation, aggregation and degranulation in JAK3-deficient platelets. Genetic perturbation of JAK3 also resulted in impaired platelet spreading and in vitro thrombus formation on a collagen-coated surface under high arterial shear rates. More importantly, thrombotic vascular occlusion after FeCl3-induced injury in vivo was blunted in jak3-/- chimeric mice, whereas no prolongation of bleeding time was observed in these mice. To address the mechanisms of CRP-triggered Ca2+-dependent platelet activation in jak3-/- mice, we analyzed PIP2 and downstream IP3 levels. By employing ELISA assays, lipidomic analysis as well as immunoblots, the observed significantly decreased PIP2 and IP3 levels in platelets from jak3-/- mice resulted from diminished levels of upstream phosphatidylinositol-4-phosphate 5-kinase (PIP5K).
Conclusions: The present study reveals JAK3 as a regulator of PIP2 and IP3 generation in platelets with subsequent Ca2+-dependent activation, dense granule secretion and aggregation upon GPVI stimulation. Finally, JAK3-deficiency results in decreased in vitro and in vivo thrombus formation, without affecting bleeding time. Therefore, JAK3 could play a decisive role in arterial thrombosis underlying myocardial infarction or ischemic stroke and may represent a druggable target in future improved treatment regimens of cardiovascular diseases.